CNBG says it will work in partnership with Abu Dhabi-based artificial intelligence and cloud computing firm G42 to conduct testing and local production of vaccines. He did not disclose details such as the date or the number of people she plans to register for the test.
The world is in full development, vaccination programs are in motion in the final phase of testing before they are approved for inoculation for the general public. Pharmaceutical companies around the world are competing to be the first to find an effective blow against the new coronavirus, which has infected more than 9.2 million people and killed more than 476,000 others.
CNBG is the first Chinese vaccine developer to pursue a Phase III trial to test whether the two shots it has developed are effective against pathogens.
Chinese companies have had to look for other places with active virus outbreaks to complete the final phase of human testing, which requires thousands of people. The small number of cases in China has made it impossible for them to conduct such tests at home. READ. A. E. is still adding hundreds of cases a day, with a total of more than 45,000 infections.
Chinese biotech CanSino Biologics Inc. was approved last month to conduct human tests for the vaccine, it co-developed with the Chinese military in Canada, but will need to re-start safety studies before d ” enter the Phase III trial. Based in Beijing, Sinovac Biotech Ltd. in partnership with the Butantan Institute the deployment of the test of its shooting on 9000 people in the hot spot of Brazil, but has not yet won the authorization to proceed. Vaccine candidates from companies outside of China are also leading for Phase III trials. A co-developed coup by the University of Oxford and AstraZeneca Plc will be tested among the 2,000 people in Brazil starting this month. Cambridge, Massachusetts, according to Moderna Inc. is set to start testing its hit next month in a 30,000-person trial in the US The two shots developed by CNBG have already been tested in some 2,000 people in phase I and II of the trials carried out in China. One vaccine has been found to be generally safe, while data for the other will be released on June 28. The shots have already been administered to more than 1,000 employees, including senior executives from CNBG and its parent company.
Employees of Chinese state-owned companies have also reportedly been offered voluntary shots from the CNBG vaccines if they are traveling for work abroad or if they live in high-risk areas in Beijing, which recently saw a new epidemic of the virus.
© 2020 Bloomberg L. P.